







# Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



**Notes:**

1. The above is an extract of the detailed format of the standalone and consolidated financial results for the quarter and Nine Month ended 31st Dec, 2019 filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. the full format of the standalone and consolidated Financial Results for the quarter ended 31st Dec, 2019 are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.indswiftlabs.com
2. Company has achieved standalone EBITDA of Rs. 40.08 crore in this quarter as compared to EBITDA amount to Rs. 40.04 crore in corresponding quarter of last year.
3. The Company has adopted Ind AS 116 on "Leases" with effect from April 1, 2019, applied all contracts of leases existing on April 1, 2019 by using modified retrospective approach and accordingly, comparative information for the year ended March 31, 2019 has not been restated. The Company has recognised and measured the Right-of-Use (ROU) asset and the lease liability on the remaining lease period and payments discounted using the incremental borrowing rate as at the date of initial application. The effect of adoption of Ind AS 116 on the results and earnings per share for the Quarter and Nine month Ended ended 31st December, 2019 is not material.
4. In terms of Regulation 32(1) of the SEBI ( LODR) Regulations, the funds raised raised through NCDs and OCDs issue, have been fully utilised for the specific purpose for which the funds were raised and there is no deviation(s) or variation(ss)of utilisation of funds thereon. The Company has created security on the listed NCD.
5. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end.
6. The previous period figures have been re-grouped, re-arranged and reinstated wherever necessary.
7. The Company is exclusively in the Pharmaceutical Business segment.
8. The above standalone and consolidated results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 13th February, 2020.

For IND SWIFT LABORATORIES LIMITED

N.R Munjal  
Chairman and Managing Director

